Bridgeway Capital Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-36,100
| Closed | -$849K | – | 1316 |
|
|
2024
Q2 | $849K | Buy |
+36,100
| New | +$849K | 0.02% | 733 |
|
|
2023
Q2 | – | Sell |
-6,000
| Closed | -$43.5K | – | 1446 |
|
|
2023
Q1 | $43.5K | Hold |
6,000
| – | – | ﹤0.01% | 1318 |
|
|
2022
Q4 | $67.5K | Buy |
+6,000
| New | +$67.5K | ﹤0.01% | 1267 |
|
|
2022
Q3 | – | Sell |
-1,946
| Closed | -$25K | – | 1450 |
|
|
2022
Q2 | $25K | Sell |
1,946
-2,974
| -60% | -$38.2K | ﹤0.01% | 1307 |
|
|
2022
Q1 | $283K | Buy |
+4,920
| New | +$283K | 0.01% | 1096 |
|
|
2020
Q2 | – | Sell |
-4,580
| Closed | -$534K | – | 1397 |
|
|
2020
Q1 | $534K | Buy |
4,580
+480
| +12% | +$56K | 0.01% | 740 |
|
|
2019
Q4 | $783K | Hold |
4,100
| – | – | 0.01% | 802 |
|
|
2019
Q3 | $788K | Hold |
4,100
| – | – | 0.01% | 794 |
|
|
2019
Q2 | $702K | Hold |
4,100
| – | – | 0.01% | 866 |
|
|
2019
Q1 | $825K | Hold |
4,100
| – | – | 0.01% | 833 |
|
|
2018
Q4 | $768K | Hold |
4,100
| – | – | 0.01% | 839 |
|
|
2018
Q3 | $981K | Buy |
4,100
+100
| +3% | +$23.9K | 0.01% | 887 |
|
|
2018
Q2 | $1.06M | Hold |
4,000
| – | – | 0.01% | 862 |
|
|
2018
Q1 | $992K | Hold |
4,000
| – | – | 0.01% | 841 |
|
|
2017
Q4 | $541K | Hold |
4,000
| – | – | 0.01% | 1067 |
|
|
2017
Q3 | $474K | Hold |
4,000
| – | – | 0.01% | 1109 |
|
|
2017
Q2 | $384K | Buy |
+4,000
| New | +$384K | ﹤0.01% | 1156 |
|